Precision Decisions for Building Precision Therapies

Flagship Biosciences helps drug developers confidently define a path to success.
Upcoming Conference: Connect with us at Immuno-Oncology 360, Feb. 1-3

Make Clear Decisions with Quantitative and Contextual Tissue Data

Learn more about Flagship's Computational Tissue Analysis (cTA™) Platform and Decision Support Process for tissue biomarkers.

Achieve Success with Actionable Data


cTA™
Platform

  • Combines histology and digital pathology
  • Quantifies cell-based biomarker content
  • Delivers contextual relationships

Decision Support Process

  • Pathologist-directed data collection
  • Statistical data interpretation
  • Science-driven
    decision making

Your Success

  • Understand complex pharmacodynamic responses in tissue context.
  • Develop robust efficacy hypotheses to guide tissue-based data interpretation and patient selection.
  • Design and execute more efficient and successful clinical strategies.
  • Quickly and efficiently adapt to a dynamic competitive landscape.
LEVERAGE YOUR BIOMARKERS FOR SUCCESS

Utilizing a patient selection biomarker in oncology clinical trials increases success 3-fold from phase 1 to approval.

2016 BIO Biomedtracker Amplion report

The Value of Tissue-Based Biomarkers

Tissue-based biomarkers provide the necessary context to understand the biological content which determines patient phenotype and drug response.

Mouse-over or tap on the image below to see the context surrounding the content shown.

THE IMPORTANCE OF ROBUST TISSUE BIOMARKER DATA

Only 3-5% of exploratory biomarkers end up used in oncology clinical practice. This small number of successes are likely due to “inappropriate methodological foundation and impertinent biological interpretation”

de Gramont, A. et al. Nat. Rev. Clin. Oncol. 12, 197–212 (2015)

Technology for Confident
Tissue Context Data

THE PROBLEM:

Semi-quantitative, variable data is used to make
precision decisions

Difficulties in tissue interpretation increase time, cost, and risk of failure, as has been demonstrated in the competitive, evolving PD-L1 landscape.


THE SOLUTION:

Use quantitative, reproducible data to make
precision decisions

Flagship Biosciences helps leverage the benefits of tissue-based biomarkers, while reducing the risk and time associated with relying on a pathology based patient selection strategy.
A technology which can meet the CHALLENGE

Flagship uses computer models that are too complex for me to understand; but the data helps me understand my biomarker.

-Director of Clinical Research, large pharmaceutical company